Doxepin

Critical Warnings & Restrictions (Safety-First)

Basic Doxepin Information

• INN (International Nonproprietary Name): Doxepin (doxepin hydrochloride) is the WHO‑approved INN and is a tricyclic antidepressant used for major depressive disorder, anxiety disorders, chronic pruritus and low‑dose insomnia.
• Brand Names Available In Australia: Deptran is listed as an Australian brand for systemic doxepin (capsules/tablets).
• ATC Code: Primary ATC code N06AA12 for doxepin; dermatologic ATC D04AX01 applies to topical antipruritic formulations.
• Forms & Dosages: Marketed worldwide in capsules, tablets, oral solution and topical cream forms.
• Manufacturers In Australia: Not specified.
• Registration Status In Australia: Not specified.
• OTC / Rx Classification: Not specified.

Doxepin is a tricyclic antidepressant with important safety considerations in everyday pharmacy practice.

Known risks include marked sedation and anticholinergic effects such as dry mouth, constipation and urinary retention.

Orthostatic hypotension is possible and increases fall risk in older people.

Cardiac effects include QT prolongation and conduction abnormalities, so enquire about heart disease and cardiac medications before supply.

Younger adults starting antidepressants can experience a transient increase in suicidal ideation, so monitor mood and suicidality closely.

Check for history of glaucoma, urinary retention, severe constipation, bipolar disorder, epilepsy and severe liver impairment before initiating doxepin.

Avoid concurrent or recent monoamine oxidase inhibitor (MAOI) therapy due to serious interactions.

Pharmacists must confirm current TGA product information and PBS guidance before dispensing.

Counsel patients to avoid alcohol while stabilising on doxepin and to report palpitations, syncope, severe dizziness, urinary retention or severe constipation promptly.

Document counselling and check the patient’s medicines list for interacting antidepressants, anticholinergics, antiarrhythmics and relevant CYP inhibitors or inducers.

• Checklist For Counselling And Safety Documentation:
• Confirm indication and recorded diagnosis.
• Confirm dose, formulation and start date.
• Explain common and serious adverse effects.
• Give driving and workplace safety advice.
• Arrange follow‑up and note monitoring plan.

High-Risk Groups (Elderly, Pregnancy, Chronic Illness)

Elderly

Increased sensitivity to anticholinergic effects, orthostatic hypotension, cognitive impairment and falls.

Pregnancy And Breastfeeding

Limited data on safety; weigh maternal benefits against potential neonatal withdrawal, sedation and anticholinergic effects and consult obstetric specialist with shared decision documentation.

Liver Impairment

Reduce dose and monitor for toxicity because doxepin is hepatically metabolised.

Cardiac Disease

Baseline ECG advised for patients with cardiac risk factors and avoid in uncontrolled arrhythmias.

Epilepsy

Doxepin lowers seizure threshold and should be used with caution under specialist guidance.

Paediatric Use

Not routinely recommended for depression in children without specialist input.

Mental Health Comorbidity

Screen for bipolar disorder prior to initiation and consult psychiatry for mood stabiliser co‑management if indicated.

Tricyclic antidepressant classification is relevant for drug selection and risk review in these groups.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Doxepin commonly causes sedation and slowed reaction time, so warn patients about driving and operating machinery until they know how they react.

Australian road laws can still apply if a driver’s capacity is impaired by prescribed medication, so caution patients that driving while impaired may be an offence.

Advise avoidance of driving for several days after starting or increasing dose until sedation is assessed.

Employers in safety‑critical industries may require medical fitness clearance for staff taking sedating medications.

Document all safety advice in the patient record and provide written warnings when sedation is reported.

• Practical Checklist For Activity Safety Advice:
• Advise no driving until individual response known.
• Recommend starting on evenings or weekends where possible to assess sedation.
• Warn against alcohol or sedative polydrug use.
• Provide written advice and note a follow‑up review.

Suggested Patient Counselling Script:

• “This medicine often makes people drowsy or slow to react; do not drive or operate machines until you know how it affects you.”
• “Avoid alcohol and other sedating medicines while you are getting used to doxepin.”
• “If you work in a safety‑critical role, check with your employer or treating clinician before returning to full duties.”

Q&A — “Can I Drive After Taking It In Australia?”

• Short Answer: Not until you know how doxepin affects you and sedation has subsided.
• Expect drowsiness, slowed reactions and possible blurred vision for several days after starting or increasing dose.
• If sedation or cognitive impairment persists, do not drive because apparent impairment may breach Australian road safety law.
• Discuss dosing time with the prescriber; bedtime dosing is common where sedation is marked.
• Contact the treating clinician or pharmacist for documented advice if in a safety‑critical role.

Usage Basics

INN, Brand Names Available In Australia

Doxepin (INN: doxepin hydrochloride) is a tricyclic antidepressant available in systemic and topical forms.

Australian brand examples include Deptran for systemic capsules and tablets.

Topical doxepin creams equivalent to Zonalon or Prudoxin are used for pruritus in other markets and may be supplied or compounded locally when indicated.

• Common Strengths And Formulations:
• Deptran 10 mg, Deptran 25 mg, Deptran 50 mg capsules or tablets.
• Oral solution and topical 5% cream formulations used for pruritus.
• Availability varies by state and pharmacy supplier; check local stock and TGA registries.

Legal Classification (TGA‑Approved, PBS‑Listed)

• Verification Checklist For Dispensing:
• Confirm prescription authenticity for telehealth e‑prescriptions.
• Check PBS item number and repeats before supply.
• Document authority prescriptions and clinical rationale where required.

Dosing Guide

Standard Regimens (PBS Reference Dosing)

• Starting, Titration And Maximum Dose Guidance:
• For depression or anxiety, start low and titrate—common starting range 25–75 mg daily in divided doses.
• Maintenance regimens vary; severe cases may be titrated up to 150–300 mg daily with specialist oversight and reference to product PI.
• Low‑dose use for insomnia uses small doses at bedtime in jurisdictions with low‑dose products; check TGA guidance for Australian approval.
• Topical 5% cream is applied thinly to affected skin for pruritus as per dermatology guidance.
• Nordic DDD index defines systemic daily dose as 100 mg orally.

Adjustments For Comorbidities

• Dose Adjustment Checklist:
• Reduce starting dose for elderly patients and reassess frequently.
• Lower dose and prolong titration in hepatic impairment due to hepatic metabolism.
• Renal impairment usually requires fewer adjustments but consult specialist if severe renal disease is present.
• Abrupt cessation is discouraged; taper over 1–2 weeks to reduce withdrawal symptoms.
• Consider baseline ECG and ongoing cardiac monitoring for patients with cardiac risk.
• Serum doxepin levels are not routine; monitor clinically for toxicity signs.

Suggested Monitoring Timeline: baseline review, follow up within 1–2 weeks after start or dose change, then regular reviews as clinically indicated.

Q&A — “What If I Miss A Dose?”

• If a single dose is missed take it when remembered unless the next dose is due soon; do not double up.
• For once‑daily bedtime doses, skip a missed dose if it is near the next scheduled dose.
• If several doses are missed or treatment was stopped for days contact the prescriber—re‑titration from a lower dose may be needed.
• For topical use continue the next scheduled application and avoid excessive re‑application to prevent local irritation.

Interaction Chart

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Common Drug Conflicts

Major interacting classes include MAOIs, SSRIs/SNRIs, anticholinergics, antihistamines, opioids, benzodiazepines, antiarrhythmics and strong CYP2D6 or CYP3A4 inhibitors or inducers.

MAOIs are contraindicated because of severe interactions.

Combined use with SSRIs or SNRIs raises risk of serotonin syndrome and additive QT prolongation in some cases.

Anticholinergic medicines and antihistamines add to dry mouth, constipation and urinary retention risks.

Use pharmacy dispensing software and PBS e‑medication lists to flag important interactions at supply.

• Quick Reference Interaction Checklist:
• Check for recent MAOI use and allow appropriate washout periods.
• Flag concurrent antidepressants and antiarrhythmic drugs.
• Review all OTC anticholinergic products and antihistamines before supply.
• Consider ECG monitoring when combining with other QT‑prolonging drugs.

User Reports & Trends

What patients commonly report when discussing doxepin in Australian forums and review sites?

• Common Positives:
• Symptom relief for pruritus with topical formulations.
• Improvements in sleep maintenance at low doses for some patients.
• Established antidepressant efficacy where other agents were unsuitable.
• Common Negatives:
• Sedation, weight gain and dry mouth are frequently reported.
• Some patients note a delayed mood benefit, typically 2–6 weeks.
• Rural patients report brand variability and occasional supply delays affecting adherence.

Anecdotal reports should be interpreted cautiously and discussed with the treating clinician for clinical decisions.

Access & Purchase Options

National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)

Major Australian pharmacy chains typically stock generic and some branded doxepin products, but availability depends on supplier agreements and local demand.

Price sensitive patients often compare Deptran prices and generic doxepin capsules between chains.

• Pharmacist Checklist For Supply:
• Check stock and confirm brand or generic equivalence.
• Verify PBS script requirements and repeats prior to supply.
• Advise on substitution and expected differences in appearance or packaging.

Online Pharmacies And Telehealth E‑Prescriptions

E‑prescribing and telehealth are widely used in Australia for initiating and continuing doxepin therapy.

Ensure electronic prescriptions are authorised and patient identity is verified before dispensing remotely.

Licensed Australian online pharmacies must have an Australian practice site and a registered pharmacist review orders.

For rural patients, mail delivery can improve access but consider heat protection in summer and delivery delays.

In our online pharmacy, doxepin is available without a prescription, with discreet delivery to Australia in 9-21 days.

• Safe Purchase Steps:
• Use registered Australian pharmacy websites only.
• Confirm prescription authenticity for prescription items.
• Avoid overseas suppliers without TGA import approval.

Mechanism & Pharmacology

Simplified Explanation

Mechanism

Doxepin non‑selectively inhibits reuptake of norepinephrine and serotonin, increasing synaptic neurotransmitter levels.

Main Receptor Actions

Strong H1 antihistamine activity explains sedation and antipruritic effect in topical use.

Clinical Consequences

Therapeutic effects include antidepressant and anxiolytic effects systemically and pruritus relief topically, but anticholinergic side effects are common.

Clinical Terms

Indications & Off-Label Uses

Approved Indications By TGA

• Doxepin is primarily used systemically for major depressive disorder and anxiety disorders.
• Topical formulations are used for chronic pruritus.
• Low‑dose doxepin is used for insomnia in some jurisdictions; check TGA product information for Australian approvals.
• Confirm TGA labels before prescribing and dispensing to match approved indications.

Off‑Label Uses In Australian Clinical Practice

• Low‑dose doxepin may be used off‑label for insomnia where antihistaminic sedation is desired and other options are unsuitable.
• Dermatologists may use topical doxepin for pruritic dermatoses when first‑line therapies fail, subject to local supply arrangements.
• Off‑label prescribing should include informed consent and documentation of rationale and expected monitoring.

Checklist For Off‑Label Prescribing Documentation:

• Record indication, benefits, risks and alternative options discussed.
• Obtain and document patient consent for off‑label use.
• Plan follow‑up and monitoring with prescriber and pharmacist notes.

Key Clinical Findings

What the evidence says from older trials and more recent reviews between 2022 and 2026.

• Evidence Strengths:
• Older randomised trials support doxepin’s efficacy in depression and anxiety compared with placebo and older antidepressants.
• Comparative studies show similar antidepressant effects to other TCAs but generally less tolerability than SSRIs for many patients.
• Topical 5% cream demonstrates symptomatic relief for chronic pruritus in clinical trials.
• Low‑dose doxepin shows benefit for sleep maintenance in some randomised controlled trials, with variable regulatory approval across countries.

Australian clinicians should compare current guidelines and TGA product information when applying this evidence to practice.

Alternatives Matrix

PBS‑Listed Alternatives Comparison Table

Pros And Cons Checklist

• Pros: effective for depression and anxiety in many patients, low‑dose option useful for insomnia, topical form useful for pruritus, long clinical experience.
• Cons: anticholinergic burden, sedation, falls risk in the elderly, cardiac conduction effects and numerous drug interactions.
• Patient Factors To Consider: age, cardiac history, liver function, pregnancy/breastfeeding, concomitant medicines, work and driving requirements.

Common Questions (Pharmacy FAQs)

• How Long To Wait For Effect: mood benefits typically take 2–6 weeks.
• Expected Side Effects: sedation, dry mouth, constipation and blurred vision are common.
• Missed Doses: follow the dosing Q&A guidelines and contact prescriber if multiple doses missed.
• Interactions With Alcohol And Other Medicines: avoid alcohol and review all medicines for interactions.
• Pregnancy/Breastfeeding Safety: limited data—consult obstetric services and document shared decision‑making.
• Stopping The Drug: taper gradually to reduce withdrawal symptoms.

Scripted Pharmacist Replies For Common Questions:

• “Start low and titrate slowly, and we will arrange a follow up in 1–2 weeks to check tolerance.”
• “Avoid alcohol and other sedative medicines while you are getting used to doxepin.”
• “If you or someone close notices worsening mood or suicidal thoughts contact the prescriber or emergency services immediately.”
• “Seek urgent care for chest pain, palpitations, fainting or severe anticholinergic effects.”

Price & Access Comparison Table

Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required

Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

• Call ahead to confirm stock or place an order for Deptran or generic doxepin.
• Verify whether substitution is acceptable and document any brand change.
• Confirm postage options and delivery times for online orders, with packaging protection for summer heat.
• Discuss concession cards, PBS safety‑net and potential cost savings with the patient.
• For urgent dermatologic pruritus, coordinate with prescriber for short supply or compounding if topical cream is not stocked.

Registration & Regulation

TGA Approval

• Use the TGA ARTG database to verify registration of specific doxepin products before supply.
• Systemic and topical formulations may have different ARTG entries and approved indications.
• Confirm approved dosages and sponsor details in the ARTG entry.

PBS Subsidy Details

Document prescribing rationale when authority prescriptions are used to support PBS claims.

Storage & Handling

Household Storage In Australian Climate (Heat/Humidity)

• Store oral doxepin at room temperature away from excessive heat and humidity; avoid bathroom storage.
• Keep topical creams in a cool place away from direct sunlight and heat.
• Secure medicines out of reach of children and pets; topical creams can cause sedation if ingested.
• Dispose of out‑of‑date medicines via pharmacy return programs.

Cold‑Chain Handling For Pharmacies

• Most doxepin formulations do not require refrigeration; check the product PI for exceptions.
• Maintain documented storage temperatures in pharmacy stock records.
• For mail orders in hot weather use insulated packaging or advise customers on same‑day collection where feasible.

Guidelines For Proper Use (Patient & Pharmacist Counselling)

Australian Pharmacist Counselling Style

• Explain the purpose of doxepin clearly—whether for depression, anxiety, pruritus or sleep at low dose.
• Outline the expected timeline for benefit and common side effects.
• Give clear interaction warnings about alcohol, sedatives and other medicines.
• Use teach‑back to confirm patient understanding and provide written information and follow‑up instructions.
• Record counselling in the patient record and communicate any concerns to the prescriber promptly.

Suggested Script Snippet:

• “This medicine can make you sleepy; take it at night when starting and avoid alcohol. Please come back in 1–2 weeks or sooner if you feel worse.”

Patient Advice From PBS And National Health Authorities

Resources

Encourage patients to check PBS patient information and TGA product information for current guidance.

Follow‑Up Schedule

Recommend GP review within 1–2 weeks of initiation or dose change and urgent review for worsening mood or suicidal thoughts.

Topical Advice

Instruct correct application of topical cream and monitor for local irritation or unexpected systemic effects.

Delivery Across Australia